

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Jin-an JIAO, et al.

U.S.S.N.: **Not yet known**

Art Unit: Not yet assigned

FILED: Herewith

Examiner: Not yet assigned

FOR: ANTIBODIES FOR INHIBITING BLOOD COAGULATION AND METHODS
OF USE THEREOF

.....
CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office To Addressee" **Label No. EV342612917US** in an envelope addressed to the: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on **July 11, 2003**.

By: *Patricia A. Barnes*
Patricia A. Barnes

.....

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Date July 11, 2003

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. **LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION**

The patents, publications or other information submitted for consideration by the Office are listed on PTO-1449, attached hereto. With the exception of references BF and BG, copies of the references are not enclosed since it is believed that those references were fully considered in one or more of the parent cases. If the Examiner requires another copy of any of the references, the undersigned will promptly provide same on request.

II. **COPIES**

- a. ☐ Submitted herewith is a legible copy of (i) each U.S and foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.

III. CONCISE EXPLANATION OF THE RELEVANCE
(check at least one box)

- a. ☐ Except as may be indicated below in (b), all of the patents, publications or other information are in the English language or were cited in an English language Search Report, a copy of which is attached hereto (concise explanation not required).
- b. ☐ A concise explanation of the relevance of all patents, publications or other information listed that is not in the English language is as follows:
- c. ☐ The following additional information is provided for the Examiner's consideration:

FEES

IV. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(b)
(check one box)

- a. ☐ within three months of the filing date of a national application (37 C.F.R. § 1.97(b) (1)). No fee or certification is required.
- b. ☐ within three months of the date of entry of the national stage as set forth in §1.491 in an international

application (37 C.F.R. § 1.97(b) (2)). No fee or certification is required.

- c. ☐ before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b) (3)). No fee or certification is required. In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the certification under 37 C.F.R. § 1.97(e) below, or, if no certification has been made, charge our deposit account a fee in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p).

V. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(c):
(check one box)

before the mailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c) (1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c) (2)).

- a. ☐ No certification; therefore, a fee in the amount of \$180.00 is required by 37 C.F.R. § 1.17(p).
or
- b. ☐ See the certification below. No fee is required.

VI. CERTIFICATION UNDER 37 C.F.R. § 1.97(e) (check only one box)

The undersigned hereby certifies that

- a. ☐ each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or
- b. ☐ no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.
- c. ☐ Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned certifies that each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months

prior to the filing of this IDS. As to the remaining information, the undersigned hereby certifies that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

- ☐ Please charge Deposit Account No. 04-1105 in the amount of \$180.00 for the above-indicated fee. A triplicate copy of this paper is attached.
- ☒ No fee is required.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule (with a petition, if necessary) and charge the appropriate fee to Deposit Account No. 04-1105.

Respectfully submitted,

Date: 11 July 03



Robert L. Buchanan, (Reg. No. 40,927)
EDWARDS & ANGELL, LLP.
P. O. Box 9169
Boston, MA 02209
Tel: (617) 439-4444
Fax Nos.: (617) 439-4170 / 7748

Customer No.: 21874

#341300



21874

PATENT TRADEMARK OFFICE

[illegible]

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	DOCKET: 46943-CIP3 (71758)		SERIAL NO.: Not yet known
	APPLICANT(S): Jin-an JIAO, et al.		
	FILING DATE: Herewith	GROUP NO.: Not yet assigned	
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)			
	AI	C. Schlueter et al., <i>J. Mol. Biol.</i> , 256:859-869 (1996).	
	AL	C. Wulfig et al., <i>J. Mol. Biol.</i> , 242:655-669 (1994).	
	AM	I. Kurucz et al., <i>Proc. Natl. Acad. Sci. USA</i> , 90:3830-3834 (1993).	
	AN	S. Parmley et al., <i>Gene</i> , 73:305-318 (1988).	
	AO	G. Smith et al., <i>Methods in Enzymology</i> , 217:228-257 (1993).	
	AQ	W. Soo Hoo et al., <i>Proc. Natl. Acad. Sci. USA</i> , 89:4759-4763 (1992).	
	AS	A. Lin et al., <i>Science</i> , 249:677-679 (1990).	
	AU	N. Gasciogne et al., <i>Proc. Natl. Acad. Sci. USA</i> , 84:2936-2940 (1987).	
	AV	R. Mariuzza et al., <i>The Journal of Biological</i> , 264(13):7310-7316 (1989).	
	AW	J. Kappler et al., <i>Proc. Natl. Acad. Sci. USA</i> , 91:8462-8466 (1994).	
	AX	Rao et al., <i>Thrombosis Research</i> , 56:109-118 (1989).	
	AY	Fiore et al., <i>Blood</i> , 80(12):3127-3134 (1992).	
	AZ	Clarke et al., <i>The Journal of Immunology</i> , 145:2286-96 (1990).	
	BA	Ragni et al., <i>Circulation</i> , 93:1913-1918 (1996).	
	BB	George et al., <i>Macromolecular Sequencing and Synthesis</i> , Alan Riss, pp. 127-149 (1988).	
	BC	Groves et al., <i>Hybridoma</i> , 6(1):71-76 (1987).	
	BD	Illustrated Dictionary of Immunology, Cruse et al., CRC Press (1995).	
	BE	Morrison, <i>Ann. Rev. Immunol.</i> , 10:239-265 (1992).	
EXAMINER:		DATE:	

